Resistance to EGFR-targeted therapy: a family affair.

Vlacich G, Coffey RJ
Cancer Cell. 2011 20 (4): 423-5

PMID: 22014569 · PMCID: PMC3616495 · DOI:10.1016/j.ccr.2011.10.006

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

Copyright © 2011 Elsevier Inc. All rights reserved.

MeSH Terms (0)

Connections (2)

This publication is referenced by other Labnodes entities: